Antimycobacterial Drug Class List

Drugs in Drug Class: Antimycobacterial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xgen Pharms	STREPTOMYCIN SULFATE	streptomycin sulfate	INJECTABLE;INJECTION	064210-001	Jun 30, 1998		RX	No	Yes
Hikma	PYRAZINAMIDE	pyrazinamide	TABLET;ORAL	081319-001	Jun 30, 1992	AB	RX	No	Yes
Macleods Pharms Ltd	PYRAZINAMIDE	pyrazinamide	TABLET;ORAL	212541-001	Jul 27, 2020	AB	RX	No	No
Novitium Pharma	PYRAZINAMIDE	pyrazinamide	TABLET;ORAL	080157-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No

Antimycobacterial Market Dynamics and Patent Landscape: What Matters for R&D, Licensing, and Investment

Last updated: April 26, 2026

How big is the antimycobacterial market and where is growth coming from?

Antimycobacterial demand is driven by (1) persistent TB incidence globally, (2) rising burden of drug-resistant TB, and (3) the procurement model that links “who can supply” with WHO and national TB programs. Value concentrates around multi-drug regimens, with premium pricing and supply contracting where efficacy in resistant disease is proven.

Global demand drivers

• Drug-resistant TB (DR-TB) is the primary growth engine for newer antimycobacterial drugs because it expands the number of eligible patients for second-line and later-line regimens.
• Program procurement cycles favor manufacturers with proven quality systems, reliable manufacturing capacity, and established regulatory pathways in high-burden geographies.
• New regimen adoption typically lags clinical readouts due to guideline cycles, reimbursement rules, and tender timelines.

Revenue concentration pattern

• Revenue in antimycobacterial therapy is heavily concentrated in a limited set of agents that anchor guideline-recommended regimens (including TB and selected non-tuberculous mycobacteria use cases).
• Breakthrough economics often hinge on whether a product becomes a core regimen component rather than an add-on.

What determines commercial outcomes in antimycobacterial drugs?

The class has a consistent set of commercial determinants.

Uptake mechanics

• Guideline inclusion drives volume more than pipeline differentiation alone.
• Efficacy in drug-resistant populations is a major determinant of payer and tender decisions.
• Fixed-dose combinations (FDCs) and regimen simplicity influence procurement because they reduce dosing complexity and supply fragmentation.

Competitive switching dynamics

• In DR-TB, regimens are constrained by resistance profiles and prior exposure. Switching is driven by:
  • Demonstrated activity in specific resistance patterns.
  • Compatibility with backbone drugs used in local protocols.
  • Manufacturing and supply reliability in high-burden countries.

Pricing reality

• Pricing power is strongest when:
  • The drug replaces multiple prior components (regimen consolidation).
  • The product is needed for specific resistant indications.
  • There is limited alternative supply.

What is the current patent landscape structure in antimycobacterial drugs?

The antimycobacterial patent landscape is shaped by three themes that repeat across developers:

1. Second-generation improvements
   • New salts, polymorphs, crystalline forms, and process improvements around existing drug candidates.
2. Regimen-level IP strategy
   • Patents covering combinations, dosing regimens, and treatment methods.
3. Long-tail IP around fixed-dose combinations
   • Combinations and FDC systems can create multiple layers of protection beyond the original NCE/biologic composition.

Practical implication for portfolio design

• A developer can defend a product even when the “headline molecule” nears expiry by:
  • Extending protection on solid form and manufacturing.
  • Owning dosing regimens and combination methods.
  • Filing jurisdiction-specific secondary patents to delay generic entry.

Where are patent expiries most likely to impact competition?

Patent cliffs in antimycobacterial therapy typically do not create “clean” generic substitution. Instead, they trigger:

• Tender renegotiation windows,
• Contract re-bidding,
• Faster uptake of generics and authorized generics where regimen guidance allows.

Key expiry impact zones

• Core components of standard regimens face the fastest generic pressure.
• DR-TB add-ons with narrow resistance coverage may see slower generic switching unless efficacy is demonstrated against the same patient subsets.
• FDCs face fewer substitution options due to combination formulation and dosing constraints.

Which antimycobacterial products have defined IP battlegrounds?

This section covers major, widely cited antimycobacterial assets that have shaped the patent conversation. The legal landscape has been active across geographies, with disputes typically centered on composition, formulation, polymorphs, and method-of-use claims.

Representative IP pressure points (high level)

• Nitroimidazole-class TB regimens and resistance contexts
  Developers frequently seek secondary patents for solid form and dosing schedule refinements.
• Fluoroquinolone derivatives and TB bactericidal activity
  Patenting tends to include salt/solid form and combination method claims.
• Ethambutol and rifamycin-related products
  Secondary IP often covers specific formulations, FDCs, and treatment protocols.

(Note: Specific, current litigation status and exact expiry dates require jurisdiction-by-jurisdiction verification. This response is constrained to market and landscape dynamics without producing potentially incorrect legal event data.)

How do innovators structure patent thickets in this therapeutic area?

Antimycobacterial innovators typically deploy multi-layer IP stacks.

Composition and formulation layers

• New salts and hydrates to improve stability and manufacturability.
• Polymorph and crystal form patents to extend exclusivity.
• Particle size distribution and process parameter claims where allowed.

Method-of-use layers

• Treatment methods for DR-TB patient subsets defined by resistance profile or prior therapy.
• Dosing regimens that map to clinical trial schedules.
• Combination method claims with a defined partner drug or a defined sequence.

Combination and FDC layers

• Patents that cover:
  • The fixed combination composition and ratio,
  • The packaging and dosing schedule,
  • Storage stability and release profiles.

What is the role of regulatory exclusivity alongside patents?

In antimycobacterial therapy, regulatory exclusivity can extend market protection even where patents approach expiry.

Typical exclusivity levers

• Data protection periods for novel clinical submissions.
• Market exclusivity rules where applicable in each jurisdiction.
• Pediatric extensions where frameworks exist.

Commercially, exclusivity can:

• Delay generic approvals,
• Slow tender replacement even where supply of generics is available.

How do biosimilar-style dynamics translate to antimycobacterials?

Antimycobacterial drugs are mostly small molecules; they do not face biosimilar pathways. Instead, the competitive analog is:

• Generic entry under ANDA-style pathways in markets that permit generic substitution,
• Authorized generic and tender-managed competition.

The patent landscape remains the key gating mechanism.

What does the market require from pipeline candidates to win?

Pipeline candidates win when they clear three hurdles:

1. Efficacy in DR-TB
   • Demonstrated activity in the resistance scenarios that matter for guideline uptake.
2. Regimen compatibility
   • Ability to integrate with backbone therapies used by programs.
3. Operational manufacturability
   • Reliable API supply, scalable synthesis, and stable formulation to survive tender scale.

Patent value is highest when it protects these three realities via:

• Method-of-use claims for regimen settings,
• Solid form/process patents that support scale,
• Combination claims that align with how programs actually procure and dispense.

---

Key Takeaways

• Demand is anchored by TB and DR-TB, with growth tied to resistant patient volumes and guideline-driven regimen adoption.
• Patent landscapes in antimycobacterials are multi-layered: solid form, process, method-of-use, and combination/FDC claims typically overlap.
• Competition does not follow simple patent expiry. Generic switching is shaped by regimen guidance, resistance compatibility, and tender contracting cycles.
• IP is most valuable when it covers how drugs are used, not just the molecule, since procurement and guideline inclusion determine volume.

FAQs

1) Do antimycobacterial patent cliffs cause rapid generic substitution?

Usually not. Tender cycles and guideline changes slow switching; method-of-use and combination patents often delay practical substitution.

2) Which IP types most often extend exclusivity beyond the primary composition?

Secondary solid-form patents (salts, polymorphs), process improvements, and regimen-level method-of-use and combination/FDC patents.

3) What drives adoption of new antimycobacterial therapies in DR-TB?

Efficacy in resistance-defined populations plus regimen compatibility with backbone therapies used in national TB programs.

4) Where is patent thicketing most common in the class?

In assets that become regimen anchors and in candidates expected to be used in combination or fixed-dose formats.

5) What matters more for market impact: molecule novelty or regimen placement?

Regimen placement usually determines volume. Patents that cover regimen use and combinations can protect that placement longer.

---

References

1. World Health Organization (WHO). Global tuberculosis report. (Latest available edition on WHO website at time of access).
2. European Medicines Agency (EMA). Public assessment reports and medicines information on antimycobacterial agents.
3. U.S. Food and Drug Administration (FDA). Drug approvals and exclusivity information for antimicrobial/antimycobacterial drugs.
4. WIPO (World Intellectual Property Organization). Patent landscape and IP policy resources relevant to pharma second medical use and formulation protection.